EAGLE PHARMACEUTICALS, INC.: Nasdaq/NYSE listing notice — Eagle Pharma faces potential Nasdaq delisting after 10-K delay; may miss extension deadline

EAGLE PHARMACEUTICALS, INC.

Received Nasdaq notice on April 8 for failure to timely file FY 2023 Form 10-K; prior Q3 10-Q also late.
Company previously granted extension to May 13, 2024 to regain compliance; must submit updated plan by April 23.
Company believes it is unlikely to file Form 10-Q or 10-K by May 13 extension deadline.
Nasdaq may accelerate delisting; company could request hearing to stay suspension.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

EAGLE PHARMACEUTICALS, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 8, 2024, Eagle Pharmaceuticals , Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”), with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with t

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-046776

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.